Forte Biosciences announces oversubscribed $53 million private placement

seekingalpha
20 Nov 2024
  • Forte Biosciences (NASDAQ:FBRX) on Wednesday announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102.
  • "We expect to advance FB102 into additional indications over the next 12 months. 2025 could be an exciting year of clinical milestones for FB102," said Paul Wagner, Chief Executive Officer of Forte Biosciences.
  • FBRX +19.49% premarket to $7.08.
  • Source: Press Release

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10